

Resource Summary Report

Generated by ASWG on Aug 10, 2026

SGLT-2 Antibody (D-6)

RRID:AB_2814658

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-393350, RRID:AB_2814658

Antibody Information

URL: http://antibodyregistry.org/AB_2814658

Proper Citation: Santa Cruz Biotechnology Cat# sc-393350, RRID:AB_2814658

Target Antigen: SGLT-2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: WB, IP, IF, IHC(P), ELISA

Antibody Name: SGLT-2 Antibody (D-6)

Description: This monoclonal targets SGLT-2

Target Organism: rat, mouse, human

Clone ID: [D-6]

Antibody ID: AB_2814658

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-393350

Record Creation Time: 20250819T232946+0000

Record Last Update: 20250820T053102+0000

Ratings and Alerts

No rating or validation information has been found for SGLT-2 Antibody (D-6).

No alerts have been found for SGLT-2 Antibody (D-6).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Gu L, et al. (2026) SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(14), e72142.

Conte E, et al. (2025) SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure. European journal of pharmacology, 997, 177617.

Carneiro de Oliveira K, et al. (2024) Tubular deficiency of ABCA1 augments cholesterol- and Na⁺-dependent effects on systemic blood pressure in male mice. American journal of physiology. Renal physiology, 326(2), F265.

Herat LY, et al. (2023) SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes. iScience, 26(8), 107260.